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It is a sobering thought that as we approach the 21st century, breast
cancer remains one of the most prevalent of all carcinomas, with
one in eight women in Western societies being expected to develop
the disease at some point in her life. Research examining those
factors affecting the development of breast cancer has identified
that steroid hormones are of pivotal importance in directing the
growth of these tumours. This knowledge has been exploited clin-
ically, with endocrine treatments which seek to perturb the steroid
hormone environment of the tumour cells often promoting exten-
sive remissions in established tumours and furthermore providing
significant survival benefits for patients (Nicholson et al, 1992).
Unfortunately, the beneficial actions of existing endocrine
measures are, in part, counteracted by the capacity of the tumour
cells to eventually circumvent the need for steroid hormones,
allowing them to continue to grow and progress despite such
therapy (Gee et al, 1996; Nicholson et al, 1996). Thus, at presenta-
tion of breast cancer, current endocrine therapies are not effective
in all patients (de novo endocrine resistance), while initially-
responsive tumours will sooner or later progress despite such treat-
ments (acquired resistance), inevitably resulting in patient relapse
and, ultimately, death. Identification of the factors and pathways
responsible for the development of these resistant conditions is
therefore an important diagnostic and therapeutic goal in cancer
research.
One proposed model for such loss of steroid hormone sensi-
tivity in breast cancer in both the de novo and acquired setting
suggests that aberrations advantageous to tumour cell growth
occur specifically within important growth factor signalling path-
ways, allowing mitogenesis to proceed highly efficiently despite
the challenge of endocrine therapy. A new paradigm is thus
emerging where knowledge of the tumour expression of growth
factor signalling elements may be prognostically relevant in 
identifying endocrine responsiveness, and where appropriate 
anti-growth factor signalling therapeutic regimens, in combination
with antihormonal measures, would be expected to be beneficial to
breast cancer patients (Nicholson et al, 1999a).
In this light, the present review seeks to outline the elaborate
molecular biology of oestrogen and growth factor signalling
pathway interactions which are likely to play a central role in
hormone sensitive breast tumour growth. It subsequently exam-
ines how changes often occurrent in the breast cancer phenotype
might severely perturb the balance of such signalling, thus
providing a possible explanatory hypothesis for the tumour growth
associated with the phenomena of de novo and acquired endocrine
resistance. A discussion of how such data might be therapeuti-
cally-exploitable in breast cancer has been published elsewhere
(Nicholson et al, 1999a, 1999b).
‘Cross-talk’ between steroid hormone and growth
factor signalling pathways influences the growth of
endocrine responsive disease
Many studies have now identified that breast tumours which
exhibit an effective endocrine response (i.e. complete and partial
response) are often histologically low grade, well-differentiated
and notably oestrogen receptor (ER)-positive with a minimal level
of proliferation at presentation (Williams et al, 1986; Bouzubar 
et al, 1989; Robertson et al, 1989; Nicholson et al, 1991, 1993;
Locker et al, 1992; Cheung et al, 1997). The 40–50% of breast
cancer patients bearing such tumours frequently enjoy a long dura-
tion of response and survival time (Nicholson et al, 1984). In such
tumours, it is likely that ER signalling is central to mitogenesis,
with steroid hormone occupancy of the receptor efficiently driving
cell growth and survival together with expression of target genes
bearing either oestrogen response elements (ERE) (Nicholson 
et al, 1999a, 1999b; Seery et al, in press) or composite response
elements which bind receptors in addition to other transcription
factors (Diamond et al, 1990). However, it is increasingly
proposed that such events proceed most efficiently in an appro-
priate growth factor environment, with steroid hormone and
growth factor signalling pathways ‘cross-talking’ to reinforce each
others’ signalling. While many of the relevant growth factors and
their receptors are expressed by the breast cancer epithelial cells
themselves, thereby potentially working in an autocrine manner,
additional paracrine factors may be liberated from the surrounding
stroma. In each instance, several potential points of interaction
between steroid hormone and growth factor signalling pathways
have been identified. A number of these are detailed below and are
illustrated in Figure 1.
The ER is a target for growth factor-induced kinase activity
(Figure 1.1)
Numerous studies have now shown that the ER protein is subject
to phosphorylation and activation by several peptide growth
factors (e.g. IGF1 [Aronica and Katzenellenbogen, 1993], EGF,
transforming growth factor-a [TGF-a, Bunone et al, 1996] and
heregulin [Pietras et al, 1995]), events which can subsequently
initiate ERE-mediated gene expression (Ignar-Trowbridge et al,
1996; Lee et al, 1997). These events are believed to be effected by
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which has been shown to activate ER possibly by a direct phos-
phorylation of serine 118 located in the A/B region of the ER
(Kato et al, 1995). Additional transduction molecules demon-
strated to target the ER to date include casein kinase II, pp90rsk1,
protein kinase C d, cyclin A/cdk2, Rho pathway elements and
p60c-src (Ali et al, 1993; Arnold et al, 1994, 1997; Le Goff et al,
1994; Casalini et al, 1997; Trowbridge et al, 1997; Zwijsen et al,
1997; Joel et al, 1998; Lahooti et al, 1998; Rubino et al, 1998;
Tzahar and Yarden, 1998). Significantly, growth factors and
downstream signal transduction pathways appear to differential-
lyregulate the two transcriptional activator functions of the ER
(i.e. AF-1 and AF-2), with the former being more responsive to
EGF, TGF-a and mitogen activated protein (MAP) kinase
signalling (Bunone et al, 1996). While activation by these factors
occurs most efficiently in the presence of oestrogens, their promo-
tion of AF-1 and AF-2 responses certainly appears adequate for
initiating transcription in the absence of the steroid hormone. An
increasing number of additional cell signalling pathways appear to
also impact on the bioactivity of ER, including the pineal hormone
melatonin (Ram et al, 1995), neurotransmitters such as dopamine
(Gangolli et al, 1997), and second messengers including cAMP
(Cho and Katzenellenbogen, 1993). An emerging concept for
steroid hormone receptors is therefore that they function not only
as direct transducers of steroid hormone effects but, as members of
the cellular nuclear transcription factor pool, also serve as key
points of convergence for multiple signal transduction pathways
(McDonnell et al, 1995).
Oestrogens stimulate positive elements of growth factor
signalling pathways, including cell attachment factors which
may facilitate growth factor-directed cell proliferation (Figure
1.2)
Oestrogen sensitivity and endocrine response have been exten-
sively investigated in experimental models of human breast cancer
both in vitro and in vivo. Based on these studies (Gee et al, 1996;
Nicholson et al, 1996), it is becoming increasingly evident that
oestrogens can promote the autocrine expression of growth factor
signalling pathway components (Figure 1.2a), notably TGF-a
(Bates et al, 1988), IGF-II (Brunner et al, 1993) and growth factor
receptors (e.g. epidermal growth factor receptor [EGFR; Berthois
et al, 1989] and IGF-IR [Freiss et al, 1990]), in oestrogen-respon-
sive (MCF-7 and T47-D) and oestrogen-dependent (ZR-75-1)
human breast cancer cell lines. In the latter instance, the IGF-IR
has also been shown to be activated by oestrogen (Richards et al,
1996; Guvakova and Surmacz, 1997), subsequently recruiting
downstream signalling components, notably including insulin
receptor substrate-1 (IRS-1; Richards et al, 1996; Guvakova and
Surmacz, 1997), which in turn may be oestrogen-regulated
(Westley et al, 1998). Such actions, which are often antagonized
by anti-oestrogens (Gee et al, 1996; Nicholson et al, 1996), could
significantly supplement the cellular growth responses directly
primed by oestrogens (Cho and Katzenellenbogen, 1993; Smith et
al, 1993). In addition, it appears that oestrogens directly stimulate
(while anti-oestrogens inhibit) the tyrosine kinase activities both
of the EGFR-related protein c-erbB-2 (Matsuda et al, 1993) and of
c-src (Migliaccio et al, 1993), the activation of which can provide
important mitogenic signals to epithelial cells (Figure 1.2b)
through the recruitment of the p21ras/Raf/MAP kinase pathway
(James et al, 1994; Troppmain et al, 1994).
Commonly, the frequency with which a cell divides in vitro 
is dependent upon its adherence, increasing as cells spread out
over the extracellular matrix. This may not only facilitate
increased nutrient uptake, but also the ability of the cell to capture
growth factors, this being particularly evident at focal adhesion
contacts which function as sites for priming of intracellular signals
(Weisberg et al, 1997). In this light, oestrogens in addition to
stimulating growth factor signalling pathways directly, can
promote cell–cell and cell–matrix adhesion (Millon et al, 1989; 
De Pasquale, 1998), thereby facilitating growth factor directed 
cell proliferation. Oestrogens have thus been shown to induce
laminin receptor, together with various extracellular matrix
components and cell membrane adhesion proteins (Castronovo 
et al, 1989), events which may be blocked by anti-oestrogens
(Millon et al, 1989). Indeed, the anti-oestrogen toremifene has
been shown to inhibit the phorbol ester enhanced a2 b1 integrin-
dependent adhesion of MCF-7 breast carcinoma cells (Maemura et
al, 1995).
Oestrogens inhibit negative elements of growth factor
signalling pathways (Figure 1.3)
As well as the positive influences exerted by oestrogens on growth
factor signalling pathways detailed above, it is notable that in
parallel they diminish (while anti-oestrogens induce) the expres-
sion of the growth inhibitory factor TGF-b (Knabbe et al, 1987) in
several oestrogen-responsive human breast cancer cell lines.
Oestrogens thus serve to inhibit the expression of a factor impli-
cated in the induction of programmed cell death (Perry et al, 1995)
and which acts through the p38/Jun kinase (JNK) pathway (Hill,
1996).
Additionally, however, it is of particular significance that
oestrogens have been reported to inhibit expression of tyrosine
phosphatases in ER-positive breast cancer cells to increase growth
factor mitogenic activity, while both steroidal and non-steroidal
anti-oestrogens increase phosphatase activity (Freiss and Vignon,
1994; Freiss et al, 1998). Tamoxifen, for example, inhibits the
mitogenic activity of EGF by promoting significant dephosphoryl-
ation of EGFR, an effect believed to be ER-mediated (Freiss et al,
1990; Freiss and Vignon, 1989). It appears that such EGFR-
dephosphorylation is accomplished via an increase in tyrosine
phosphatase activity, as evidenced not only by an effective inhibi-
tion by sodium orthovandate (a broad-spectrum phosphatase
inhibitor), but furthermore by a time- and dose-dependent increase
in membrane phosphatase activity with the anti-oestrogen (Freiss
and Vignon, 1998). In this light, two tyrosine phosphatases have
been identified which appear to be regulated by oestrogens and
anti-oestrogens, LAR and FAP-1 respectively (Freiss et al, 1998).
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Figure 1 Cross-talk between ER and growth factor signalling pathways. 
ER, oestrogen receptor; ERE, oestrogen response element; GF, growth
factor; GFR, growth factor receptor; NTF, nuclear transcription factor; RE,
response elementSignificantly, antisense inhibition of FAP-1 expression abolishes
the anti-oestrogen-mediated inhibition of growth factor mitogenic
activity, although the ‘pure’ anti-oestrogen ICI 182,780 appears to
retain inhibitory activity under these conditions suggesting that the
effects of this compound are FAP-1-independent (Freiss et al,
1998).
The ER interacts with growth factor-induced nuclear
transcription factors, co-activators/co-repressors and
additional proteins to target a diversity of response
elements (Figure 1.4)
An important feature of growth factor signalling is its potential to
activate several profiles of nuclear transcription factors which
subsequently serve to promote the expression of genes partici-
pating in a diversity of end points, including cell cycle progres-
sion. For example, in addition to its phosphorylation of the ER
protein, growth factor-induced MAP kinase (ERK1/2) directly
activates Elk-1/p62TCF (Gille et al, 1995). This latter transcription
factor subsequently forms a ternary complex with p67SRF (serum
response factor) and primes Fos expression via the c-fos serum
response element (Gille et al, 1995). Similarly, JNK (also a
member of the MAP kinase family [Paul et al, 1997; Lewis et al,
1998]) phosphorylates the c-Jun protein which subsequently
heterodimerizes with Fos (Minden et al, 1994). The resultant
complex, AP-1, is of central importance since it directly targets the
12-O tetradecanoyl-phorbol-13 acetate-responsive element (TPA-
RE), a sequence found in the promoters of many genes involved in
a plethora of cellular end points, including proliferation and
survival (Pfahl, 1993).
In this light, it has been reported that oestrogens can signifi-
cantly enhance growth factor induced AP-1 activity in hormone
sensitive breast cancer cells (Phillips et al, 1993). This feature is
believed to be a consequence of productive protein–protein inter-
actions between the ER and the AP-1 complex (Rochefort, 1995),
a phenomoneon also recently demonstrated to occur between ER
and the transcription factor SP-1 (Porter et al, 1997; Duan et al,
1998; Sun et al, 1998; Xie et al, 1999). Thus, ER appears able to
activate genes containing AP-1 sites in their promoters (Webb et
al, 1995), providing a mechanism whereby ER signalling may be
markedly diversified. Initial studies suggested that anti-oestrogens
antagonized growth factor induced AP-1 activity, with maximal
inhibition by pure anti-oestrogens (Phillips et al, 1993). However,
subsequent investigations (albeit performed in uterine cells) have
suggested that the tamoxifen–ER complex may also act agonisti-
cally on promoters regulated by the AP-1 site (Webb et al, 1995).
In contrast to the above, ER may repress the activity of the tran-
scription factor NF-kB (Nakshatri et al, 1997), which regulates
expression of many cytokines (such as IL-6) and growth factors
(Sharma and Narayanan, 1996). aER-dependent inhibition of IL-6
again appears to be mediated via a direct protein–protein interac-
tion with NF-kB (Ray et al, 1997).
Finally, it should be remembered that ER/ERE-mediated gene
transcription is also significantly enhanced by the recruitment of
several co-activators and/or by overcoming the effects of co-
repressor proteins (McDonnell et al, 1992) that may feasibly be
regulated by growth factor signal transduction pathways (Hanstein
et al, 1996; Smith et al, 1996). Indeed, an increasing number of co-
activators and co-repressors that can interact with the ER have
been described (Parker, 1998), including the co-activators SRC-1,
RIP-140 and AIB1 (Anzick et al, 1997; Smith et al, 1997; Parker,
1998), and the co-repressors Ssn6 and SMRT (McDonnell et al,
1992; Smith et al, 1997; Lavinsky et al, 1998). Of particular
interest is the co-activator CREB-binding protein (CBP)/p300,
which is believed to be a component of multiple signalling path-
ways including cAMP signal transduction (Hanstein et al, 1996;
Smith et al, 1996). Additional proteins also under growth factor
regulation have been shown to interract with the ER including the
cell cycle protein cyclin D1 (Lavoie et al, 1996). This protein can
activate ER by direct binding, as well as by recruiting co-activators
of the SRC-1 family to the ER (Zurijsen et al, 1997, 1998).
Steroid hormone and growth factor signalling pathways
influence common growth regulatory genes (Figure 1.5)
In order for cells to proliferate, they initially need to be recruited
into the cell cycle and then be induced to progress through it.
These outcomes are orchestrated by at least two series of events
which can be jointly influenced by steroid hormone and growth
factor signalling pathways (Musgrove et al, 1993; Prall et al,
1998): firstly, the induction of intermediate early response genes,
such as c-fos (Morishita et al, 1995; Duan et al, 1998), c-jun
(Morishita et al, 1995; Mohamood et al, 1997) and c-myc (Dubik
and Shiu, 1992; Musgrove et al, 1993), and secondly, the regula-
tion of G1 cyclins (e.g. cyclin D1) and their partner kinases and
inhibitors which are involved in restriction point control
(Musgrove et al, 1993; Lukas et al, 1996). Joint activation of these
pathways by oestrogens and growth factors would at a minimum
reinforce mitogenic signals to responsive cells, and might even
result in synergistic interactions between overlapping elements.
Additionally, it is likely that steroid hormones (Kyprianou et al,
1991) and many growth factors (Amundadottir et al, 1996; Werner
et al, 1997; Wang et al, 1998) influence the expression of cell
survival factors in endocrine responsive cells, such as the bcl-2
protein (Huang et al, 1997; Wang et al, 1998).
Changes in the tumour cell phenotype potentially
perturb ‘cross-talk’ between oestrogen and growth
factor signalling pathways in endocrine unresponsive
disease (Figure 2)
The above data generated largely from model systems provides
compelling evidence that many points of convergence exist for
oestrogen- and growth factor-mediated signalling pathways, and
that it is likely that growth responses in endocrine responsive
breast cancers hence proceed more efficiently in a mixed
oestrogen and growth factor milieu. In such tumours, although
reductions in input signals from steroid hormones appear sufficient
to promote extensive tumour remissions, there is an increasing
body of evidence to suggest that phenotypic changes which would
severely perturb the balance of steroid hormone and growth factor
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Figure 2 Changes in breast cancer phenotype which may influence
endocrine response‘cross-talk’ may underlie the phenomenon of in vivo endocrine
unresponsiveness in breast cancer.
EGFR and other members of the erbB receptor tyrosine
kinase family
Clinical data emerging in the late 1980s and early 1990s has
convincingly shown a significant inverse relationship between the
expression of the EGFR (reviewed in Klijn et al, 1992; Nicholson
et al, 1994) and endocrine sensitivity in breast cancer. Thus, while
patients whose tumours express low levels of EGFR frequently
benefit from antihormonal drugs such as tamoxifen, women whose
tumours express unusually high numbers of binding sites for
EGF/TGF-a (Nicholson et al, 1989) or significant cell membrane-
associated EGFR immunostaining (Nicholson et al, 1994) are
largely de novo endocrine unresponsive. Although to some degree
these associations may be simply explained by the inverse rela-
tionship known to exist between the oestrogen and EGFR, with ER
negativity thus being commonly associated with EGFR positivity,
nevertheless a direct involvement of the EGFR in growth
responses in endocrine unresponsive disease has been suggested,
with increased EGFR levels directly correlating both with elevated
tumour proliferation and poor prognosis (Nicholson et al, 1997a,
1997b). Such a growth input would be likely to be pivotal to ER-
negative/EGFR-positive tumours, since their lack of steroid
hormone receptor expression would obviously preclude steroid
hormone receptor mitogenic signalling. In addition, such an input
might also be important to the proportion of de novo resistant ER-
positive tumours maintaining elevated EGFR expression, since the
absence of second-line responses in such patients similarly indi-
cates a dislocation from steroid hormone receptor signalling.
Importantly, the inverse association between ER and EGFR also
occurs at a cellular level (Sharma et al, 1994b, 1994c), where the
long-term action of oestrogen is to suppress the expression of the
EGFR (Berthois et al, 1989). In this light, it has been suggested
that antihormonal measures which deprive breast cancer cells of
oestrogens may consequently encourage increased cellular expres-
sion of the EGFR, a phenomenon perhaps culminating in the
development of an acquired endocrine-resistant phenotype
deriving an increased growth stimulus from EGFR signalling.
Interestingly, this is a common phenotypic feature of endocrine-
resistant breast cancer cells generated in vitro following either
long-term exposure to anti-oestrogens or prolonged oestrogen
deprivation (Gee et al, 1996; Nicholson and Gee, 1996), as exem-
plified by our own ‘in house’ acquired resistant MCF-7 sub-lines.
Surprisingly, clinical and experimental data would suggest that
such cells rarely lose all ER expression in parallel (Gee et al, 1996;
Nicholson and Gee, 1996; Robertson, 1996), and as such the
tumour re-growth hallmarking antihormonal relapse must be
biologically distinct from the 20–30% of tumours displaying an
ER-negative/EGFR-positive endocrine unresponsive phenotype at
the time of clinical presentation (Nicholson et al, 1997a,b).
Tumour expression of an additional erbB family member, the 
c-erbB2 protein, has similarly been associated with endocrine
unresponsiveness (Nicholson et al, 1993). Indeed, tumour co-
expression of both EGFR and c-erbB2 appears to be associated
with particularly aggressive phenotypes which lead to poor prog-
nosis and resistance to endocrine treatment (Nicholson et al,
1997a, 1997b). This may be a direct result of the formation of
heterodimeric receptor complexes which are highly efficient in
their transmittance of mitogenic signals, conferring a cellular
ability to escape the growth restraints exerted by hormonal
therapy. In contrast, however, although interactions between either
EGFR or c-erbB2 and an additional family member c-erbB3
synergistically enhance their mitogenic and transforming activity
on 3T3 fibroblast cells in vitro (Alimandi et al, 1995; Wallasch et
al, 1995; Tzahar et al, 1996), readily detectable levels of c-erbB3
(and c-erbB4) are surprisingly more frequent in well-differentiated
ER-positive endocrine responsive clinical breast cancer, where
EGFR (and often c-erbB2) expression is at its lowest (Knowlden
et al, 1998). Patterns of expression (and therefore potentially the
heterodimeric interactions) of the erbB family members thus
appear to vary dramatically between hormone-sensitive and de
novo insensitive disease. Given the increased expression of EGFR
and the resultant overt sensitivity to an EGFR selective tyrosine
kinase inhibitor, ZM 1839 exhibited by our MCF-7 cells emergent
either following long-term antihormonal exposure or prolonged
oestrogen deprivation, it is similarly likely that changes in these
receptor patterns are a general feature of the acquired endocrine
resistant state (McClelland and Nicholson, in preparation).
Importantly, however, second-line endocrine responses occur in
many acquired resistant breast cancer patients. Moreover, there is
significant expression of the steroid hormone receptor at relapse,
and in vitro inhibitory studies with the pure anti-oestrogen ICI
182780 confirm that ER is functional and actively contributory
towards acquired tamoxifen- and oestrogen-resistant breast cancer
growth. These data thus identify a maintained importance for ER
(and hence potentially ‘cross-talk’) in acquired resistant growth
that is also potentially EGFR-driven.
TGF-a and other erbB receptor ligands
Enhanced production of TGF-a has been observed in transformed
rodent and human fibroblast and epithelial cells, where it may func-
tion as a downstream intermediary in the transformation pathway
elicited by oncogenes (Salomon et al, 1990). It has been suggested
that TGF-a may act to induce hyperplastic responses in trans-
formed breast cells, and thereby act as a promotional agent in
combination with a normal background of mutational events
(Matsui et al, 1990; Sandgren et al, 1990). Certainly, TGF-a has
been demonstrated to be present in readily detectable amounts in
clinical breast cancer specimens (Ciadello et al, 199; Lundy et al,
1991; Umekita et al, 1992), where its increased expression has been
related to primary endocrine insensitivity in ER-positive disease
(Nicholson et al, 1994), possibily through substantial ligand-
independent activation of the ER as noted to occur experimentally.
Furthermore, our recent examination of sequential clinical breast
cancer biopsy specimens obtained during tamoxifen treatment is
also supportive of elevated TGF-a protein expression being
involved in acquired endocrine resistance in ER-positive disease,
while diminished expression appears to be a therapeutic feature of
those patients exhibiting a good quality and longer duration of
initial response (Gee et al, in preparation). Although to date no
direct associations have been reported between the cellular levels
of TGF-a and ER/ERE-mediated events in vivo, ER-positive and
ER-negative tumours with elevated cellular levels of TGF-a show
an increased growth fraction, as monitored with the Ki-67 antibody
(Nicholson et al, 1994, 1997a, 1997b). These data certainly suggest
that elevated expression of this growth factor may comprise an
integral part of the driving force behind the growth of many breast
cancers, or may at least confer a significant growth or survival
advantage upon such cells (Nicholson et al, 1994, 1999a, 1999b).
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cellular levels of other ligands for the erbB family of receptor tyro-
sine kinases and endocrine response, multiple studies have shown
that breast tumours express variable amounts of EGF and
amphiregulin (ligands for the EGFR), together with heregulin a, b
and g and betacellulin (ligands for c-erbB3/4 [Lupu et al, 1995,
1996]). In this light, our preliminary examination of relevant
ligands for the erbB family has indicated that expression of the
mRNA for heregulin b1 (reported to be the most potent ligand for
the c-erbB3 receptor) is associated with ER and c-erbB3 positivity
in well-differentiated tumour types and is inversely associated
with EGFR (Knowlden et al, in preparation). ErbB signalling in
well-differentiated tumour cells would appear, therefore, biased
towards c-erbB3/4, while anomalous increased expression of
TGF-a/EGFR/c-erbB-2 in endocrine-insensitive disease may
direct tumour growth response pathways away from their strict
reliance on oestrogens, possibly towards substantial ligand-
independent activation of the ER.
IGF family
Many clinical breast carcinomas contain membrane-bound recep-
tors for IGFs, and their ligands, IGF-I and IGF-II, are generally
more potent mitogens for human breast cancer cells than either
TGF-a or EGF (Gee et al, 1996, Nicholson et al, 1999a). Indeed,
there is an increasing body of evidence demonstrating that IGF
signalling plays a significant role in growth and survival of
endocrine-responsive cells particularly under steroid-rich condi-
tions (Arteaga et al, 1989), where synergistic interactions with
oestrogens have been reported (Westley et al, 1989). Additionally,
both IGF-I and IGF-II reputably influence the in vitro expression
of oestrogen-regulated genes such as PR (Cho et al, 1994, Giani et
al, 1998), Fos (Wosikowski et al, 1992) and the novel oestrogen-
regulated gene pLIVI (El-Tanani and Green, 1997b), a gene that
may have a role in directing metastatic spread in ER-positive
disease (Manning et al, 1993, 1995). Although little is directly
known about the IGF receptor family and their influence on clin-
ical responsiveness of breast cancer to endocrine treatments, a
correlation has been reported between IGFR-I expression and
better clinical outcome (Papa et al, 1993). Potentially, therefore,
such tumours exhibiting productive interactions between ER and
IGF signalling may be particularly growth-sensitive to steroid
hormone withdrawal.
Interestingly, acquired resistance to tamoxifen in vitro is
reported to be accompanied by substantial increases in IGF-I
binding in MCF-7 cells (Wiseman et al, 1993), while marked over-
expression of IGFR in vitro reduces oestrogen growth require-
ments (Guvakova and Surmacz, 1997). Given the synergism
apparent between IGF and oestrogen signalling pathways, such
increases in the IGFR may serve to substantially enhance the
partial oestrogenicity which is a feature of tamoxifen, ultimately
allowing tumour cell re-growth during therapy. Similar changes
occuring in vivo in elements of the IGF signalling pathway may
feasibly contribute towards the acquired resistance phenomenon in
the clinic. Additional elements which may similarly influence the
relationship between endocrine response and IGFs include the
presence or absence of specific binding proteins (IGFBPs) which
are known to enhance or suppress IGF signalling. Breast cancer
cells have been found to express several IGF-binding proteins,
some of which are regulated by oestrogens and anti-oestrogens
(Yee, 1998).
Intracellular components of growth factor signalling
pathways
In clinical specimens, Sivaraman et al (1997) demonstrated that
hyperexpression of MAP kinase is a feature of clinical breast
cancer. In this light, our own recent studies using antibodies which
detect fully-activated erk1/2 MAP kinase have shown a highly
significant relationship between increased activation and a poorer
quality and shorter duration of response to the anti-oestrogen
tamoxifen, as well as with a reduced survival time in ER-positive
patients, while substantial increases also occur at the time of
disease relapse (Gee et al, submitted). As stated above, MAP
kinase has been shown, in addition to its inherent capacity to influ-
ence AP-1 and Elk-1 signalling, to activate the ER possibly by
direct phosphorylation on Ser-118 located in the A/B region of the
ER (Kato et al, 1995). Since this region contains the ligand inde-
pendent AF-1 domain (Tzukerman et al, 1994), it remains a possi-
bility that increased levels of activated erk1/2 MAP kinase may
contribute substantially to growth responses via AF-1 driven tran-
scriptional events originating from unoccupied or indeed anti-
oestrogen-occupied ER.
Elevated levels and/or activity of additional intracellular mole-
cules comprising growth factor signalling pathways have also been
noted in malignant breast, including pp60c-src (Lehrer et al,
1989), Grb2 (Daly et al, 1994), RHAMM (Wang et al, 1998), Ras
(Dati et al, 1991; Archer et al, 1995), Raf (Callans et al, 1995) and
protein kinase C (PKC) (Gordge et al, 1996). Importantly, in a
number of instances, overexpression of such components in ER-
positive, hormone-sensitive breast cancer in vitro following trans-
fection of appropriate vectors leads to an altered sensitivity to
hormones and antihormonal agents (Van Roy et al, 1990; El-Ashry
et al, 1997). Although the mechanisms underlying these artificially
acquired changes in endocrine response have not been fully docu-
mented, it is notable that both PKCd and c-src have, like MAP
kinase, have been suggested to target the ER, phosphorylating Ser-
122 (Lahooti et al, 1998) and Y-537 respectively (Arnold et al,
1997). Such interactions once again raise the possibility that
growth factor-induced kinase activity, in addition to directly
signalling onto specific nuclear transcription factor end points,
may alter the behaviour of the ER protein under oestrogen-
deprived or antihormone-occupied conditions, thereby generating
resistance to endocrine measures. Antihormone resistance, there-
fore, may arise from altered ER phosphorylation patterns influ-
encing its transcriptional activation.
Nuclear transcription factors
As previously stated, an important element in growth factor-
induced cell proliferation is the induction and activation of the AP-
1 complex (Davis, 1995) and elevated expression of AP-1 activity
has been observed in some human breast tumours, as compared to
normal adjacent tissue (Linardopoulos et al, 1990). The Jun
component of AP-1 is thus reported to be elevated in breast cancer
(Tinrakos et al, 1994), and importantly there is an increasing body
of in vitro and in vivo evidence to implicate the nuclear transcrip-
tion factor Fos in the control of many processes associated with the
ER-positive neoplastic breast cell, most notably in its acquisition
of endocrine independency and invasive capabilities (Gee et al,
1995). Thus, we have demonstrated significant associations
between elevated Fos protein expression and increased prolifera-
tion, de novo endocrine insensitivity (Gee et al, 1995) and further-
more a worsened patient outlook in clinical breast cancer (Gee et
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recent examination of sequential clinical breast cancer biopsy
specimens obtained during tamoxifen treatment is also supportive
of elevated Fos protein expression being involved in both primary
and ER-positive acquired endocrine resistance (Gee et al, 1999),
while diminished Fos expression appears to be a therapeutic
feature of patients with a good quality and longer duration of
response. Our clinical findings demonstrating therapeutic
increases in the Fos component of the AP-1 complex associated
with endocrine resistance are mirrored by limited in vitro studies.
As such increased AP-1 DNA binding activity has been observed
to be a feature of tamoxifen-resistant ER-positive breast cancer
cells in vitro (Dumont et al, 1996), whilst prolonged tamoxifen
exposure appears to render this anti-oestrogen agonistic in such
cells via its augmentation of the phorbol ester-inducible expres-
sion of a chimeric AP-1 response (Astruc et al, 1995; Badia et al,
1995). These studies clearly reveal the importance of AP-1/ER
signalling in directing long-term cellular responses to tamoxifen
and its agonistic/antagonistic profile.
Sadly, little is known about the relationship between ER and
additional nuclear transcription factors during the development of
either endocrine insensitivity or acquired resistance. NF-kB/Rel is
present in increased amounts in a proportion of clinical breast
cancer specimens (Dejardin et al, 1995; Sovak et al, 1997) and has
been linked to tumour progression in vitro (Nakshatri et al, 1997).
Indeed, its increased expression in two human breast cancer cell
lines has been suggested to lead to an inhibition of apoptosis
(Sovak et al, 1997). Expression of Myb (a transcription factor that
has been linked with cell cycle progression and appears to posi-
tively influence the expression of cyclin D1 [Sala and Calabretta,
1992; IGF-1 [Reiss et al, 1991] and bcl-2 [Thompson et al, 1998])
is commonly increased in ER-positive disease (Guerin et al, 1990;
Gudas et al, 1995). Finally, the Ets-related transcription factor
PEA3, a nuclear transcription factor primed by c-erbB2, appears
increased in tumours overexpressing this receptor and moreover
relates to progression in breast cancer (Benz et al, 1997). Growth
factor-directed/constitutive expression of these factors may thus
serve to influence endocrine response.
Negative elements of growth factor signalling pathways
TGF-b is the most potent known inhibitor of the progression of
normal mammary epithelial cells through the cell cycle (Reiss and
Barcellos-Hoff, 1997). In clinical breast cancer, TGF-b proteins
(Walker and Deering, 1992) or mRNAs (MacCallum et al, 1994)
are present in many samples examined, usually at significantly
higher levels than observed in the normal breast, indicating that
such cancers may often be growth-refractory to the inhibitory
activity of this factor (Travers et al, 1988, Reiss and Barcellos-
Hoff, 1997). It is notable, however, that the levels and patterns of
expression of TGF-b1–3 are highly variable (MacCallum et al,
1994).
In keeping with the reported effects of this growth factor on the
extracellular matrix (Reiss and Barcellos-Hoff, 1997), several
studies have indicated a positive relationship between TGF-b1 and
both disease progression (Gorsch et al, 1992) and lymph node
metastasis (Walker and Deering, 1992; Reiss and Barcellos-Hoff,
1997), with TGF-b1 localizing to the advancing epithelial edge of
primary tumours and lymph node metastases (Dalal et al, 1993).
Similarly, the detection of all three isoforms of TGF-b mRNA in
breast cancer specimens is associated with lymph node involve-
ment (MacCallum et al, 1994; Reiss and Barcellos-Hoff, 1997),
with TGF-b1 mRNA levels being highest in ER-positive disease
(Amoils and Bezwoda, 1997).
Although the relationship between TGF-b and endocrine sensi-
tivity of breast cancer has not been been studied in great depth in
clinical breast cancer, an early study was performed on 11 patients
who had received tamoxifen for 3–6 months prior to surgery
(Thompson et al, 1991). Unexpectedly high levels of TGF-b1
mRNA were found in patients whose tumours increased in size
and were unresponsive to the anti-oestrogen. It is possible that
progression during tamoxifen therapy may thus be due to a failure
of the autocrine inhibitory functions of TGF-b1 either alone (as
noted in in vitro [Herman and Katzenellenbogen, 1994]) or in
combination with a paracrine stimulation of stromal cells or angio-
genesis. Certainly, up-regulation of TGF-b1 mRNA in breast
cancer cells in vitro following their transfection with either v-H-
ras or TGF-b1 cDNA (Arteaga et al, 1993) leads to oestrogen
growth-independence. Such cells, however, may also show
parallel increases in TGF-a and IGF-1, together with a loss of
growth response to insulin and bFGF (Daly et al, 1995). In
contrast to the TGF-b1 clinical data, several studies have noted
that the TGF-b2 isoform increases both in tumours and in plasma
during tamoxifen therapy in responders, with no increases
recorded in initial progressors (Knabbe et al, 1996; MacCallum et
al, 1996). Interestingly, antibodies to TGF-b have been shown in a
recent study to reverse tamoxifen resistance in LCC2 breast cancer
cells (Arteaga et al, 1999), strongly implicating the pleotrophic
properties of TGF-b in the development of this condition.
Genetic events in growth factor expression and cell cycle
control
Breast cancer cells, in common with other tumour types, are
subject to genetic alterations, notably including those targeting
growth factor-associated pathways and cell cycle control elements,
and it is likely that such genetic changes would serve to markedly
influence cellular response to their steroid hormone and anti-
hormone environment (Dorssers and van Agthoven, 1996; Osin 
et al, 1998).
To date multiple activated oncogenes have been identified in
breast cancer, together with the loss of several suppressor gene
activities (Walker et al, 1997). These include an amplification of
the c-erbB2 oncogene (Seshadri et al, 1993; Ross and Fletcher,
1998), which potentially directly alters the balance of growth
factor signalling through the erbB family of receptor tyrosine
kinases (see ‘The ER is a target for growth factor-induced kinase
activity’), and elevated expression of the Ras oncogene (Dati et al,
1991; Watson et al, 1991), which in culture not only increases the
cellular output of several autocrine growth factors, but also serves
to activate the ras/raf/MAP kinase signalling cascade (Janes et al,
1994). Altered signal transduction in such cells would thus serve
to promote an increased expression and activity of multiple
nuclear transcription families (Gille et al, 1995; Whitmarsh et al,
1996; Wasylyk et al, 1998), potentially including the steroid
hormone receptors themselves (Kato et al, 1995).
Significantly, c-myc is also overexpressed in many breast
tumours, where it relates to an increased proliferative activity,
elevated tumour grade and disease spread to unfavourable sites
(Kreipe et al, 1993). In our own unpublished series, Myc expres-
sion is particularly prominent within ER-positive de novo progres-
sive disease. Although the precise molecular mechanisms which
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it is certainly interesting that Myc expression in clinical material
correlates with that of TGF-a and activated erk 1/2 MAP kinase.
Indeed, both TGF-a and MAP kinase are signalling parameters
which have been shown to impinge on and synergize with Myc in
the control of proliferation in many cancers both in vivo and in
vitro (Amundadottir et al, 1996; Gupta and Davis, 1994; Nass 
and Dickson, 1998; Santoni-Rugiu et al, 1998). Additionally,
TGF-a has also been reported to be a survival factor for mammary
tumour cells that overexpress Myc, thereby potentially enabling
increased Myc-directed cell proliferation to occur (Nass et al,
1996), while limiting any apoptosis-inducing activity known to 
be an additional feature of this nuclear transcription factor
(Amundadottir et al, 1996). Since Myc has been shown to mimic
the effects of oestradiol in promoting S phase entry (Prall et al,
1998), it is certainly feasible that Myc expression, together with
other altered elements of growth factor signalling, may be of
considerable importance in modifying endocrine response.
Additionally, our recent collaborative studies performed with
Professor Robert Sutherland (Garvan Institute, Sydney) have
demonstrated that the proportion of breast cancers overexpressing
the key cell cycle protein cyclin D1 is much greater than had
previously been appreciated from gene amplification studies of the
chromosome 11q13 locus, suggesting that aberrant transcrip-
tional/translational regulation is relatively common within such
tumours (Hui et al, 1996). In this light, while many ER-positive
tumours certainly overexpress the mRNA coding for the cell cycle
protein cyclin D1 (Buckley et al, 1993; Hui et al, 1996; Kenny et
al, submitted), interestingly its elevated expression marks a short-
ened disease-free interval, decreased time to local recurrence and
metastasis, and poor patient survival characteristics. Growth
factors signalling via erk 1/2 MAP kinase (Lavoie et al, 1996) and
Myc (Santoni-Rugui et al, 1998) appear to contribute (together
with steroid hormones [Sutherland et al, 1995]) to the regulation of
cyclin D1. An important element in this event may be the eukary-
otic initiation factor 4E (eIF4E), which is involved in regulation of
cyclin D1 expression (Flynn and Proud, 1996) and is controlled by
Ras/MAP kinase (Flynn and Proud, 1996; Sunenberg and Gingras,
1998) and Myc signalling (Jones et al, 1996). In this light, it is
interesting that eIF4E is similarly overexpressed in breast carci-
noma (Sorrells et al, 1998), where its expression again relates to
poor patient prognosis (Kerekatte et al, 1995; Li et al, 1997, 1998).
It is certainly feasible that the elevated erk 1/2 (and/or Myc)
activity frequently observed in ER-positive, progressive disease
may contribute to the marked proliferative capacity associated
with resistance via increased positive influences on cyclin D1.
Indeed, overexpression of cyclin D1 in ER-positive breast cancer
cells in vitro has been shown in one study to subsequently allow
unrestricted passage through the cell cycle, which can confer a
resistance to growth inhibition by antioestrogenic agents (Wilcken
et al, 1997b).
Interestingly, TGF-a has been observed to dramatically enhance
c-myc-induced hepatocarcinogenesis in a transgenic mouse model,
with the resultant hyperproliferative responses being not only
associated with raised cellular expression of cyclin D1, but also
with significant changes in additional components of cell cycle
regulation (e.g. intense Rb hyperphosphorylation and increased
E2F activity [Santoni-Rugui et al, 1998]). Clearly, aberrations in
growth factor signalling are likely to impinge on several key
growth/survival regulatory elements, thereby potentially influ-
encing tumour growth and hence steroid hormone/antihormone
response. Such positive effects on cell cycle progression may be
further aided by the reduced expression of the downstream medi-
ator of p53, p21/WAF-1, in many de novo endocrine-resistant
patients (Nicholson et al, 1997c; McClelland et al, 1998).
Finally, BRCA1 expression may also play a role in influencing
endocrine response in view of recent results that have shown that
its mRNA levels are indirectly elevated in breast cancer cells in
response to oestrogen (Spillman and Bowcock, 1996; Marks et al,
1997), while familial mutation associates with an endocrine unre-
sponsive phenotype (Osin et al, 1998). Indeed, we have recently
shown that BRCA1 and ER gene expression are closely associated
in clinical breast cancer, where low levels of BRCA1 expression
mark a propensity of the tumours to metastasize to distant sites
(Seery et al, 1999).
ER loss, receptor variants/mutations and sub-types
ER negativity is a relatively common event comprising some
20–30% of breast tumours at presentation, and is predictably asso-
ciated with de novo endocrine resistance (Campbell et al, 1981;
Nicholson et al, 1986, 1995; Merkel and Osborne, 1989;
Robertson et al, 1992). Although the origins of the steroid
hormone receptor-negative phenotype at presentation are as yet
unknown (Ferguson and Davidson, 1997), TGF-a/EGFR/c-erbB2
signalling, and the intracellular transduction elements MAP
kinase, PKC and AP-1, all appear of significance in relation to
growth responses (Nicholson et al, 1997a, 1997b). Relevant muta-
tions in the ER gene resulting in an inability to transcribe ER are
likely to be extremely rare in breast cancer (Ferguson et al, 1998).
However, a number of potential mechanisms preventing the effi-
cient transcription or translation of the ER gene resulting in a lack
of ER protein expression may exist. These mechanisms include: (i)
transcriptional inactivation by hypermethylation of the CpG island
in the regulatory region of the ER gene (Falette et al, 1990;
Ottaviano et al, 1994; Lapidus et al, 1996); (ii) altered expression
of transacting factors responsible for ER transcription (deConinck
et al, 1995); and (iii) abnormalities in ER translation or synthesis
of an unstable receptor protein (Ferguson and Davidson, 1997).
Alternatively, ER-negative tumours may feasibly arise from the
selective outgrowth of a sub-population of steroid receptor-nega-
tive cells which are likely to exist in the normal breast epithelium
(Walker et al, 1991, 1992), although such selective outgrowth is
reported to be very infrequent in vivo (Dowsett, 1996).
Although recent studies have revealed the ER protein may be
subject to several mutations, as well as the generation of several
truncated or exon deleted variant forms (Dowsett et al, 1997;
Murphy et al, 1997) which theoretically may alter its functionality
and ability to interact with growth factor signalling elements
(Murphy et al, 1997), in practice the ER mutations and variants
that have been noted in vivo are unlikely to provide a general
mechanism for resistance to tamoxifen therapy in ER-positive
disease (Karnik et al, 1994; Daffada et al, 1995). However, there
may be a role in breast cancer for the relatively recently-identified
ER sub-type (Dotzlaw et al, 1997; Leygul et al, 1998), ERb, and
its variants (Lu et al, 1998; Vladusic et al, 1998). In contrast to
ERa (previously referred to as ER in the current text), wild-type
ERb promotes AP-1 activity in the presence of anti-oestrogens
(Paech et al, 1997), while showing differential effects on ERE-
mediated events (Watanabe et al, 1997; McInerney et al, 1998) and
co-activator selectivity (Suen et al, 1998). Moreover, interactions
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which serve as co-activators and co-repressors of ER transcrip-
tional activity may change during breast cancer progression and
contribute to endocrine failure (Berns et al, 1998; Lavinsky et al,
1998). Unfortunately, although such proteins are often phosphory-
lated and thus potentially subject to growth factor-related kinase
activation, virtually no clinical data is available in this subject area.
Model of endocrine response and new therapeutic
targets
Increasing knowledge of the molecular biology of ER and growth
factor signalling is providing new ideas regarding the mechanisms
of action of hormones and antihormones, and moreover possible
explanatory hypotheses for the tumour growth associated with the
phenomena of de novo and acquired endocrine resistance. A
simplified working model for the transition of endocrine-respon-
sive breast cancer to endocrine insensitivity/resistance has been
compiled in summary of the data presented in this review.
In hormone-sensitive breast cancer cells, it is likely that external
signals generated by steroid hormones and stimulatory growth
factors act to induce/activate several classes of nuclear transcrip-
tion factors (e.g. steroid hormone receptor, Fos, Jun, Myc, Elk-1
etc.). These influence patterns of gene expression leading to the
gain of positive influences on cell cycle regulation (e.g. cyclin D1)
and the suppression of negative influences (e.g. TGF-b). In the
presence of adequate steroid hormone and growth factor input
signals, cells are perceived to be recruited into the cell cycle and
successfully progress through it. Equivalent pathways maintain
cell survival. Although it is likely that cross-talk between steroid
and growth factor pathways enables efficient growth signalling,
reductions in the input signals originating from steroid hormones
appear sufficient to reduce proliferation and induce programmed
cell death, thereby leading to tumour remissions. In this model,
differences between endocrine responses exhibited by normal and
cancerous cells would be expected to be minimal if oncogenic
events occurred in those cellular pathways which either act to limit
the extent of growth, but still require an input signal for growth
(i.e. which normally maintain tissue size and architecture through
negative feedback and homeostasis mechanisms), or facilitate a
more efficient use of input signals from steroid hormones.
In cancers unresponsive to current endocrine measures (Figure
3), we postulate that further alterations have occurred in those
elements of growth factor signalling pathways which:
1. Have a positive influence on steroid hormone receptor
signalling and which facilitate the biological functions of the
receptor in a lowered endocrine environment (or indeed in the
presence of antihormones which show oestrogen-like activity
such as tamoxifen). Retention of the ER protein in such cells
(as a continued orchestrator of growth responses) would facili-
tate additional responses to endocrine measures which act by
different mechanisms (i.e. aromatase inhibitor/pure anti-
oestrogen substituting for tamoxifen). Such second line
responses certainly occur in over 50% of women with acquired
resistant disease who have benefited from a first-line
endocrine response.
2. Circumvent the cellular requirement for steroid hormones via
by-passing those elements of their response pathways which
impinge on cell proliferation and survival i.e. post-receptor
mechanisms. Such phenotypic/genotypic changes may be
severe enough to override the importance of ‘cross-talk’ and
hence effectively dislocate growth from a reliance on the
steroid hormone receptor. Importantly, the majority of patients
who fail to respond to one form of endocrine therapy de novo
rarely respond to another, suggesting that the influence of the
ER in their tumour cells is entirely nullified or circumvented at
the time of presentation. This mechanism may also account for
the eventual development of acquired resistance to multiple
endocrine measures.
3. Provide a mitogenic input for tumours lacking ER. ER nega-
tivity is predictably associated with de novo endocrine resis-
tance, comprising ~20–30% of breast tumours at presentation.
Although it is as yet unknown if such a phenotype arises from
aberrant loss of the steroid hormone receptor or from selective
outgrowth of steroid hormone receptor negative cells, the
regulation of such tumours is severed from the steroid
hormone environment and they appear wholly dependent on
elements of growth factor signalling.
Based on the above model, it is clear that while the presence of
ER within tumours obviously offers an opportunity for response to
those antihormonal measures which directly target the ER, other
elements of the complex breast cancer phenotype are likely to
dictate the quality and duration of response and to be involved in
relapse mechanisms. In the future, the identification of these
elements is thus likely to be not only of great prognostic value in
identifying those women likely to benefit from existing endocrine
measures, but should promote the development of novel thera-
peutic strategies designed to delay the appearance of, treat, or even
reverse endocrine resistance, thereby severely compromising the
disease process (Nicholson et al, 1999a, 1999b). These might
potentially include the targeting of:
i. Any continued use of steroid hormone receptor signalling
ii. Aberrant growth factor signalling
iii. Cross-talk between (i) and (ii)
iv. Genetic aberrations within additional growth regulatory
components.
Although the fulfilment of these strategies will be a challenging
goal for those involved in breast cancer research (Nicholson et al,
1999a, 1999b), success should significantly extend the value of
endocrine measures and improve patient survival.
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